Collegium Pharmaceutical, Inc (COLL): Free Cash Flow
$327.58M
Year ended 2025-12-31
$328.28M
Trailing 12 months to 2026-06-30
+38.8%
3-year compound annual growth
+30.0%
5-year compound annual growth
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $327.58M | +61.1% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $203.33M | -25.9% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $274.29M | +123.7% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $122.61M | +20.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $101.61M | +15.0% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $88.40M | +314.1% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $21.34M | -87.0% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $163.91M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$68.01M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | -$75.53M | n/m | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | -$21.93M | n/m | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | -$17.95M | n/m | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | -$16.74M | n/a | 2016-03-18, From 2013-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $327.58M | +61.1% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $141.78M | -27.7% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $156.80M | +338.0% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $156.89M | n/m |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $136.66M | -23.5% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $121.23M | -29.7% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $45.99M | -73.1% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $347.89M | +59.1% |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $171.39M | +258.7% |
Compare COLL, CORT, EBS, ARWR side by side · Screen every company in Pharmaceutical Preparations ↗